Heartbeam, Inc. · NASDAQ:BEAT
Heartbeam — Q2 2023 Earnings Presentation
10 slides from Heartbeam's earnings presentation, Aug 10, 2023
Slide 1: Medical Grade Heart Attack Detection
Medical Grade Heart Attack Detection Always with the patient Second Quarter 2023 Financial Results Conference Call NASDAQ: BEAT August 10, 2023
Slide 2: Disclaimers
Second Quarter 2023 Financial Results Conference Call DISCLAIMERS This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements as to the Company’s future results of operations and financial positio
Slide 3: Agenda
Second Quarter 2023 Financial Results Conference Call Agenda • Introduction and Recent Announcements Branislav Vajdic, PhD • Strategic Focus and HeartBeam AIMIGo Update Robert Eno • Financing and Financial Results Rick Brounstein • Closing Summary Branislav Vajdic, PhD 30 years of experience in 28 y
Slide 4: Key Second Quarter 2023 and Subsequent Highlights
Second Quarter 2023 Financial Results Conference Call Key Second Quarter 2023 and Subsequent Highlights • Closed a secondary offering and registered direct offering for gross proceeds of $26.5 million to enable company to execute on upcoming clinical and regulatory milestones, and extend cash runway
Slide 5: Fundraising Activities
Second Quarter 2023 Financial Results Conference Call Fundraising Activities • Closed a secondary offering of $25 million, followed by registered direct offering of $1.5 million for a total of $26.5 million • Public Ventures LLC acted as placement agent for the offering • The funding will enable Hea
Slide 6: 2023 Strategic Focus
Second Quarter 2023 Financial Results Conference Call 2023 Strategic Focus • Immediate focus: obtaining FDA 510(k) clearance for the HeartBeam AIMIGo credit card-sized VECG device, followed by a second FDA clearance on the system’s ability to synthesize an electrocardiogram (ECG). REGULATORY • These
Slide 7: HeartBeam Product Updates
Second Quarter 2023 Financial Results Conference Call HeartBeam Product Updates • Two planned FDA 510(k) submission for HeartBeam AIMIGo • Version 1: hardware (3 lead ECG collection device) • Version 2: software, including algorithms that generate a synthesized 12L ECG for physician review • HeartBe
Slide 8: Q2 2023 Financial Highlights
Second Quarter 2023 Financial Results Conference Call Q2 2023 Financial Highlights $ in Thousands Quarters ended June 30, 2023 2022 Operating Expenses: General & Administrative $1,828 $1,793 Research & Development 1,484 1,742 Total Operating Expenses 3,312 3,535 Loss from Operations (3,312) (3,535)
Slide 9: Closing Summary
Second Quarter 2023 Financial Results Conference Call Closing Summary FINANCIAL • Closed significant funding round of $26.5 million to enable company to execute on upcoming milestones • Strong cash position provides runway to late 2024 STRATEGIC FOCUS AND PROGRESS • Adjusted strategic focus to enabl
Slide 10: Q&A
Q&A Company Investor Relations Rick Brounstein Chris Tyson Chief Financial Officer Executive Vice President HeartBeam, Inc. MZ North America ir@heartbeam.com Direct: 949-491-8235 BEAT@mzgroup.us www.mzgroup.us www.heartbeam.com 2118 Walsh Avenue, Suite 210 Santa Clara, CA 95050